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).Summary Little is known about what happens to COPD patients during their final
years of life, in particular in terms of hospital use. We linked the Swedish Mortality
and Inpatient Registers to examine this research question during the period
1987–2000.
In year 2000, 2331 fatalities were diagnosed with COPD as the underlying cause of
death. About 3% of individuals had not been admitted to hospital at all prior to their
death, whereas 15% had never been admitted for COPD (but for other reasons). More
than 68% of all COPD admissions and 74% of all days in hospital occurred in the 3.5
years before death, indicating longer stays closer to death. The last 6 months of life
accounted for 22% and 28% of all COPD admissions and days, respectively. Other
causes accounted for nearly 50% of all admissions, with a more limited increase
during the final years.
In conclusion, there is a very variable hospital use among these COPD patients.
Use increases almost exponentially as the end approaches. Finally, COPD patients
often have a number of concomittant diseases which may affect diagnosis and
healthcare resource use. The economic and policy implications of these main
findings need to be further examined.
& 2005 Elsevier Ltd. All rights reserved.Introduction
Chronic obstructive pulmonary disease (COPD) is a
worldwide epidemic, affecting almost 600 millionElsevier Ltd. All rights reserve
337879;
@astrazeneca.compeople and accounting for over 2.2 million deaths
every year.1,2 It is the only major worldwide
disorder whose morbidity and mortality are in-
creasing. While these figures are alarming, they
most certainly underestimate the true health
burdens of COPD, since airflow obstruction is an
important contributor to other common causes of
morbidity and mortality, including ischaemic heart
disease, arrhythmias and stroke.3–5d.
ARTICLE IN PRESS
Hospital use for COPD patients during the last few years of their life 1437Although COPD is becoming widely discussed in
terms of increasing mortality, morbidity and costs,
as well as decreased quality of life,1,2,6–13 rela-
tively limited information exists for individual
patterns of resource use over time. Hospital use
has been identified as being the key cost compo-
nent, both for COPD in general11 and for individuals
close to death.14 As with most other serious and
chronic diseases, there are indications that re-
source use increases the closer to the time of his or
her death the patient comes14–18; however, to the
best of our knowledge, no study has examined in
detail when the COPD-related resource use really
takes off and in what respect it does so. By mapping
this resource use in detail, one may be able to both
adapt and intensify treatment plans to improve
survival, optimise terminal care and improve
quality of life. Furthermore, this information may
be used for the planning of future healthcare needs
and organisation of healthcare.
The objective of this study was to examine
hospital care use during the last years of COPD
patients’ lives by means of frequency and diagnosis
(COPD and co-morbidity).Died in2000
(n = 2331)
Other /
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Graph 1 Those who died from COPD in year 2000—how
much were they admitted to hospital in 1987–2000, and
for what reasons.Methods
We linked the Swedish Inpatient Register and the
Swedish Mortality Register for the individuals who
died in 2000 with the underlying cause of COPD.
The Swedish Mortality Register is a nationwide
register, covering all 9 million inhabitants.19 For all
deaths in Sweden, a death certificate is required
from a doctor, preferably one who has sometime
treated the patient. In 15% of cases a post mortem
is also carried out. In about 0.5% of all deaths, the
cause of death is not recorded.
The Swedish Inpatient Register comprises data on
all inpatient bed-days and all discharges in Sweden
as per the International Classification of Diseases
(ICD-9 and ICD-10) codes.20 Up to eight reasons
(one main) may be coded for a hospital admission.
We used data for 1987 (the first year in which the
register covered the entire country) up to 2000.
Data sets are compiled annually and quality
assessments and correction of the data are per-
formed. The proportion of missing data is approxi-
mately 1% or less for most variables in this register.
We submitted a formal application and project
plan to the Swedish National Board of Health and
Welfare before being granted access to the two
registers. For reasons of confidentiality, we were
not allowed access to some personal information.
For example, the exact date of death was not madeavailable, hence we had to assume that, on
average, the death took place in mid-year.
COPD was defined as: ICD-9: 490–492, 496
 ICD-10: J40–J44
This definition is slightly broader than the GOLD1
definition but in line with a previous extensive
technology assessment study by SBU in Sweden.8
First ever hospital admission was defined as the
first hospital admission due to COPD. As we
examined a period starting in 1987, a few hospital
admissions may have occurred before that year.
The patient sample is mainly examined from
three different perspectives. Those with no COPD-
related hospital admissions, those with COPD-
related admission where COPD was the underlying
(primary) cause and finally those with admissions
where COPD was rated a being a secondary
(contributing) cause of admission.Results
In 2000, 2331 Swedes died from COPD as the
underlying cause of death, which amounts to about
2.4% of all deaths in Sweden (Graph 1). The average
age of death was 78.6 years for men and 77.2 years
for women. For the 1293 men, this was on a par
with the average age of death for all Swedish men
(life expectancy at birth), whereas for the 1038
women, it was about 5 years lower than average.19
About 50% died in hospital, although this varied
considerably, depending on which group they
belonged to in Graph 1.
Graph 1 shows that these 2331 individuals, who
died in year 2000, had a very varying hospital use.
Two-thirds (n ¼ 1530) had been hospitalised some-
time in the previous 13 years with COPD as the
underlying diagnosis, of which the great majority
had been hospitalised for other reasons as well
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admitted for COPD. Slightly less than one-third had
been hospitalised for other reasons (n ¼ 736), half
of which COPD had been a contributing cause of at
least one admission (n ¼ 384). Finally, 65 (2.8%)
individuals had at no time been hospitalised in the
13 years before they died of COPD.
The average age of death ranged from 73.7 years
for those 56 individuals who had only been
admitted for COPD, increasing to 77.0 years
for those 1530 who had been admitted for
both COPD and other reasons and to 80.3 years
for those 736 admitted but not with COPD as the
main cause.
Those 1530 individuals in whom COPD was the
underlying reason for their hospital admission had
on average close to 5.8 COPD admissions per
person, with an average of 8.4 days per admission
(Table 1) (A). If one includes those who also had
COPD as a contributing cause (6625 admission),
these 1914 individuals had on average 7.5 COPD-
related hospital admissions (B). Including all in-
dividuals with a hospital admission, irrespective of
the reason, the average for these 2266 individualsTable 1 Summary statistics for all individuals who die
between 1987 and 2000.
Resource Total
(A) Hospital admissions: COPD as
underlying cause of admission
8815 (n ¼ 1530)
Mean number of admissions per
individual
5.8
Mean number of total days per
individual
48.5
Mean number of days per
admission
8.4
(B) Hospital admissions: COPD as
underlying or contributing cause of
admission
14,440 (n ¼ 1914)
Mean number of admissions per
individual
7.5
Mean number of total days per
individual
66.4
Mean number of days per
admission
8.8
(C) Hospital admissions: All causes 28,189 (n ¼ 2266)
Mean number of admissions per
individual
11.9
Mean number of total days per
individual
111.1
Mean number of days per
admission
8.9
Note: 65 individuals were never admitted to hospital during thiswas 11.9 admissions over the previous 13 years. Of
these, on average 3.9 were for COPD only, i.e.
about 33 percent (C).
Graph 2 presents the different forms of hospital
use spread over the last 13 years of these COPD
patients’ lives. In 19.2% of cases, their first ever
COPD-related hospital admission, took place in the
6 months before they died, the median being
approximately 2.5 years before. The cumulative
admissions set out in Graph 2 show a strong
increase towards the end of life, but with a varying
intensity depending on how you measure this.
There is an increasing trend over time in the
length of stay for all COPD-related admissions
(mean ¼ 8.41 days, Graph 3). Thus, the number
of hospital admission goes up over time, while the
average length of stay increases even further in the
6–18 months before death.
The majority of hospitalisations are for other
reasons than COPD (Table 1). For example, nearly
half of the 28,189 admissions do not relate to COPD
at all and more than two-thirds (28,129–8815) have
other underlying reasons than COPD. Generally,
concomitant diseases are the common diseases ofd in 2000 from COPD and were admitted to hospital
Male Female P-values
(M vs. F)
4582 (n ¼ 814) 4233 (n ¼ 716)
5.6 5.9 0.45
46.2 51.1 0.13
8.2 8.6 0.045
7552 (n ¼ 1037) 6848 (n ¼ 877)
7.3 7.8 0.18
62.1 71.6 0.010
8.5 9.2 0.0007
14,957 (n ¼ 1257) 13,232 (n ¼ 1009)
13.1 12.4 0.012
101.4 123.2 0.0005
8.5 9.4 0.0006
period.
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Table 2 Other common reasons for hospital admissions in
admissions associated with any such reason (ICD-9 and ICD
Reasons for hospital admission At least one
COPD-related
admission
(n ¼ 1474)
N
r
a
(
Alcohol dependence syndrome 1.0 2
Acute myocardial infarction 1.3 1
Angina pectoris 2.0 1
Heart failure 3.8 5
Atrial fibrillation 1.3 o
Occlusion of cerebral arteries o1 1
Acute bronchitis and bronchiolitis 1.2 1
Pneumonia 5.5 6
Asthma 6.0 3
Bacterial pneumonia 2.0 1
Respiratory failure/disorder 7.5 4
Symptoms involving respiratory
symptoms and other chest symptoms
2.3 1
Fracture of neck or femur 2.3 4
Bladder cancer o1 o
Other malignant neoplasm of skin o1 o
Total number of non-COPD
admissions (mean per patient)
15,673 (10.6) 5
47.0
31.9
25.7
9.611.2
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Graph 2 Share of total hospital admissions and hospital
days spent in each time period before the patient died.
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Graph 3 Average length of stay (LOS) per admission in
relation to when the patient died (Po0:0001).
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diseases are also very frequent (Table 2).Discussion
This study has shown that COPD patients have a
very variable use of the healthcare system, ranging
from no COPD-related hospital admissions to a large
number of admissions over a relatively long time
period. On average, the use of hospital care
increases almost exponentially as the end ap-
proaches. We have also shown that COPD patients
often are admitted to hospital because of other
diseases.
An interesting finding that raises further ques-
tions is that about 3% were never admitted at all
before dying from COPD and 15% had at no time
been admitted for COPD. In addition, 16.5% had
only had COPD-related admissions where COPD was
judged to be a contributing cause. It is likely that
the diagnosis of COPD as the cause of death is still
underreported. Although there was no direct
method of assessing patient severity in our study,
this cohort of 2331 individuals most likely consisted
of moderate to severe COPD, as the correlation
between disease severity and severity of exacer-
bations (a severe exacerbation has previously been
defined as one requiring hospitalisation) is high.12this group of COPD patients—percentage of non-COPD
-10).
o COPD-
elated
dmission
n ¼ 736)
COPD as
contributing
cause only
(n ¼ 384)
Never admitted
for COPD
(n ¼ 352)
.4 1.1 4.2
.7 2.1 1.0
.9 2.0 1.8
.1 6.4 3.1
1 o1 o1
.9 1.7 2.3
.2 1.1 1.4
.1 6.9 4.8
.2 4.4 1.5
.5 1.7 1.2
.2 6.1 1.4
.3 1.5 1.1
.8 4.0 6.1
1 1.2 o1
1 o1 1.2
711 (7.9) 3385 (8.8) 2326 (6.6)
ARTICLE IN PRESS
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esting, and indeed, COPD and its relationship to
other diseases is something that is increasingly
being discussed in the literature.3–5,21,22
Among patients suffering from COPD, Camilli
et al.21 found that COPD was reported more often
on death certificates among patients with severe
COPD than for less severe cases. Moreover, whether
COPD was reported as a contributing cause
depended on which underlying cause was men-
tioned. For example, when ischaemic heart disease
was the underlying cause of death, COPD was
mentioned in 50% of cases as compared to 25%
when malignancy was the underlying cause.
To the best of our knowledge, no previous study is
directly applicable to the research questions of this
study, although Lynn et al.18 addressed some
related questions. They made detailed clinical
recordings of 416 COPD patients during their last
6 months of life. Patients spent between 15% and
25% of their last 6 months in hospital, mainly due to
respiratory infections and cardiovascular disease.
More than 75% had 2–3 co-morbidities. Their quality
of life was low, with 25% experiencing serious pain
and two-thirds severe dyspnoea. Anxiety and
confusion were also common.
In general population studies, researchers have
found that healthcare expenditure increases with
closeness to death.14,15,23 Mukamel examined the
last 3 years before death, finding that resource use
started to increase about 7 months before death,
with a substantial increase about 1 month prior to
death. The increase was dominated by hospital use.
The variation was, however, fairly large.14
Men who died of COPD show an average life
expectancy equal that of the general population.
As we do not have very detailed individual data for
the study population one can only speculate as to
the reasons for this finding. Cardiovascular disease
(CVD) has been found to be an important cause of
death and hospitalisation among patients with
COPD.24 In the study by Huiart et al., the rate of
hospitalisation for CVD was higher than that for
COPD itself and CVD was listed more often as the
underlying cause of death than was COPD. In
another study, which found that COPD was a
predictor of CVD hospitalisation and mortality, the
relationship of COPD to CVD outcomes was stronger
in adults who wereo65 years of age. This indicates
that COPD patients with CVD may die at a younger
age due to the CVD. In addition, the CVD risk may
be monitored and treated with particular care in
younger adults with COPD.25
In contrast, women who died of COPD lost about
5 years of life, indicating a gender difference. One
explanation could be that smoking has a greaterimpact upon the health of women. Gender differ-
ences regarding the deleterious effects of tobacco
smoking have been reported for negative effects on
lung growth, lower lung function in adulthood,
increased bronchial responsiveness, higher rate of
hospitalisation for chronic obstructive pulmonary
disease, and higher risk of respiratory symptoms.26
We used discharge and mortality registers cover-
ing all hospitals and deaths in Sweden and contain-
ing information that has been assessed as valid and
reliable19,20 from a specificity point of view, while
admittedly sensitivity has been difficult to validate.
One potential limitation is the lack of information
on the diagnostic accuracy of the registers. There
are studies indicating that doctors may fail to
diagnose as many as 25% of COPD cases and that a
misdiagnosis of asthma is common.7 Furthermore,
co-morbidities are common and affect resource
use18 and diagnostic accuracy. With regard to
deaths, only 21% of men with COPD and 6% of
women with COPD in the Tecumseh Community
Health Study had COPD recorded on their death
certificate.27 Another limitation is the 3-year time
lag before completion of the registers, which
obliged us to use data from 2000. There may be
recent shifts in patterns given the increasing
awareness of this disease,1,2 although the shift is
probably not very dramatic over just a few years.
Since 1987 there have also been a number of
therapeutic and organisational interventions which
may influence our results. Another possible limita-
tion is our assumption that deaths occurred in the
middle of the year, although this was necessary for
confidentiality and ethical reasons. If we would
have been granted access to the exact day of death
we could have examined more in detail the
patterns during the last 6 months of life. Previous
findings suggest there are seasonal variations in
mortality, as well as in hospital admissions.28 This
may reduce the precision of our results, although
difficult to quantify.
One advantage of the study is that the registers
are nationwide, covering all 9 million inhabitants in
Sweden. The quality of these population-based
registers can also be considered to be relatively
high as they preferably should be completed by the
doctor responsible for the treatment. We have also
focussed on the individuals for whom COPD was
coded as the underlying reason for the death hence
we have probably focussed on the core of deaths
due to COPD.
We believe that our main findings can be
generalised to other patient groups, countries and
settings, although the resource use is probably also
driven by the organisation of healthcare, the
availability of beds, the extent of informal care,
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disease, etc.
In conclusion, there is a very variable hospital
use among these patients who died from COPD.
Healthcare use increases almost exponentially as
the end approaches. Finally, COPD patients often
have a number of concomittant diseases which may
affect diagnosis and healthcare resource use. The
policy implications of these three main findings
need to be further examined.Acknowledgements
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